Next Phase Newsletter

A biotech angel investment fund founded in 2016 and headquartered in Taiwan has a fund size of $50M and an average ticket size range from $250K to $1M. The fund mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A multi-family office founded in 2017 has offices in multiple countries throughout Asia. The firm is jointed by 12 families and each has a minimum personal or family asset of 30 million USD. Currently, the firm has total assets under management of 34 million USD. Typical Allocations Size of the firm is around 1.5 million USD. The firm invested in 2 companies in the year 2019 and they do not have a strict limit to the number of new investments.

The firm is open to investing in general Bio-medical industries, including medical devices, healthcare IT and therapeutics. The firm has a preference for reproductive medicine and eye-related topics. Any kind of technic, device or service are welcomed under these 2 topics. Besides the topics above, the firm is currently looking for pre-clinical and phase I opportunities in therapeutic companies as well as medical devices and healthcare IT companies that are in development. Apart from the bio-medical industry, the firm also focuses on investing in E-Vehicle related startups.

The firm is looking for companies with Asia Angle, preferably Asia-based or those plan to do R&D in Asia. The firm is typically a co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Taiwan-based VC with additional offices in USA has invested primarily in Taiwanese companies, but actively considers those based in the US as well. The firm invests primarily in therapeutics and digital health. The firm looks to be an active investor, and can help those companies looking to expand to the US. The firm invests early, in seed-early stage rounds, and generally makes a first investment of between $500K-1M.

The firm primarily invests in therapeutics and digital health, although will consider investing in medical devices or diagnostics if the company is exceptional. For therapeutics technology, the firm is agnostic to indication and will invest as early as proof of concept stage, although some animal data is preferable. For digital health companies, the firm is fairly flexible with regards to stage of development and will consider most healthcare-related or IoT technologies (e.g. smart hospital applications).

The firm looks for companies with great teams, whether they are experienced entrepreneurs or not. For companies based in Taiwan, the firm prefers to lead investments and take a board seat, playing an active role after investment. For US-based companies, the firm will generally co-invest and may recommend a partner to the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A medical device of a large Chinese pharmaceutical company has 226 affiliated companies with a total of over 8,000 employees, making over 3 billion revenue each year. The firm is interested in early-stage diagnostics, medical device and healthcare IT companies, but will also consider drugs in applicable cases.

The firm is generally interested in medical devices, diagnostics, and Digital healthcare companies with a preference for healthcare platform and CFDA approved companies. The firm will look at different stage companies that are investing in angel to pre-A, and IPO companies and provide investment consulting services to the firm

The firm invests globally but prefers companies with Chinese backgrounds. The firm strongly prefers companies with at least one Mandarin speaker in the management teams. The firm is willing to work with academic researchers or companies that are in very early stages and can provide supports in commercialization using the firm’s already-established internet platforms.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An R&D subsidiary of a Chinese pharmaceutical focuses on novel therapeutics. In the meantime, the firm is also responsible for sourcing global technology assets for the parent company. The firm is interested in Therapeutics and Healthcare IT opportunities. Fully funded by the parent company, the firm’s allocation size varies for the case to case, no upper limit, and in addition to investment the firm is also interested in co-development, in-licensing, and acquiring.

The firm is especially interested in Antibody therapeutics including new structure antibodies, Gene Therapy, CAR-T Therapy, Targeted Therapy, oncolytic virus therapy, and rare disease. Any combination of AI technology and therapeutics is preferred. For therapeutics, the firm focuses on products in pre-clinical and Phase I stage and will consider orphan indications.

The firm has no specific requirements for company and management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science venture capital firm with strong China expertise and global capabilities was founded in 2017. The firm discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs.

The firm currently has two funds: The first $115 million fund has been fully invested. The firm is raising another $115 million fund, which more than half are closed. The firm operates offices in USA and China.

The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services. The firm is looking to invest from seed, first institutional round, to growth stage.

The firm has no specific requirement for the company & management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global technology company is dedicated to crafting innovative optical and digital solutions in medical technologies; life sciences; industrial solutions; and cameras and audio products.

The company’s medical business works with health care professionals to combine their innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing with their skills to deliver diagnostic, therapeutic and minimally invasive procedures to improve clinical outcomes, reduce overall costs and enhance quality of life for patients.

Throughout the company’s long history, the company has focused on being true to society and making people’s lives healthier, safer and more fulfilling. The company’s commitment to our purpose along with our major presence in hospitals around the world aligns with our goal to invest in future developments that will improve the experiences of providers and patients and transform Healthcare around the world.

The company is seeking partnerships and licensing relationships with early stage medical device startups worldwide. The company’s key areas of interest are endoscopes, laparoscopic devices, devices for minimally invasive surgery, and AI technologies across a wide range of specialties including ENT, gastrointestinal, respiratory, gynecology, and urology.

The company is interested in working with and supporting medical device companies with differentiated technology addressing unmet medical needs. An ideal partner would have an experienced management team with a proven track record of successful business development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.